S62798

S62798 is a potent, selective, and competitive small molecule inhibitor of the active form of thrombin-activatable fibrinolysis inhibitor (TAFIa, also known as carboxypeptidase B2). Developed by Servier, it is an azaphosphinane derivative designed to enhance endogenous fibrinolysis by preventing TAFIa from removing C-terminal lysine residues from fibrin, thereby promoting clot degradation with a potentially lower bleeding risk compared to traditional thrombolytics. The compound was primarily investigated as an intravenous treatment for intermediate-high risk acute pulmonary embolism, often in combination with heparin. Clinical development reached Phase II, but the program appears to have been discontinued.